- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04126967
Next Generation Sequencing(NGS)Monitors Minimal Residual Disease(MRD)in Allo-PBSCT Patients
Objective: to evaluate the value of high-throughput next generation gene sequencing (NGS) in the detection of minimal residual disease (MRD) and recurrence after allogeneic transplantation.
Overview of study design. This study is a single-center, single-arm, prospective clinical trial designed to evaluate the significance of next generation gene sequencing (NGS) in monitoring for minimal residual disease (MRD) and recurrence after allogeneic transplantation.
This clinical study is observational and does not involve drugs. Next generation sequencing (NGS) were used to monitor minor residual lesions after allogeneic hematopoietic stem cell transplantation, to predict disease recurrence early, and to monitor and evaluate prognosis, so as to provide basis for early intervention treatment after transplantation, so as to reduce hematological recurrence and improve survival rate.
This clinical study is observational and does not involve drugs.The sensitive next generation sequencing (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation, to predict the relapse of the disease in the early stage, and to monitor and evaluate the prognosis, so as to provide the basis for early intervention treatment after transplantation, so as to reduce the hematological relapse and improve the survival rate.
Study Overview
Detailed Description
Minimal residual disease (MRD) detection is the detection of residual micro-clones in patients with leukemia in remission, predicting the recurrence of the disease, and determining the next treatment of the disease.There are many methods to detect MRD, the most common one is Flow cytometry (FCM).The fusion genes of Wilms tumor 1(WT1), pml-rara, runx1-runx1t1, cbfb-myh11 and nucleophosmin(NPM1) were detected by Polymerase Chain Reaction(PCR).Chromosome analysis;Fluorescence in situ hybridization(FISH), etc.FCM is a commonly used method for clinical detection of MRD, with a sensitivity of 10-3~ 4. Its specificity is only high when there is abnormal cloning in specimens, and false negative can be caused when there is phenotypic drift and bone marrow dilution.PCR detection of WT1 is considered to be a marker of preleukaemia, but WT1 is also expressed in non-leukemic cells and is not recommended by the European leukaemia network (ELN).PCR detection of pml-rara, runx1-runx1t1, cbfb-myh11 and other fused genes only supported the clinical trial data when the log index decreased in the numerical procedure.Chromosome analysis is less sensitive because of its lack of metaphase chromosome division.FISH has a sensitivity of 10-2~ 3, specificity is only high in abnormal cells, but detection rate of mutations not covered by probes is low, and non-specific binding of probes can lead to false positives.The sensitivity, specificity and pertinence of various MRD detection technologies are different. Currently, these technologies are combined to analyze MRD clinically.
Next generation gene sequencing (NGS) is the ability to simultaneously detect the structure of all disease clones and subclones and track their changing mutations.Compared with PCR and FCM that detect abnormalities in a single clone, NGS can detect each disease clone and subclone.NGS has been clinically used to diagnose mutations and subtypes of blood diseases.Persistent mutations are associated with high recurrence rates.
This clinical study is observational and does not involve drugs.The sensitive next generation sequencing (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation, to predict the relapse of the disease in the early stage, and to monitor and evaluate the prognosis, so as to provide the basis for early intervention treatment after transplantation, so as to reduce the hematological relapse and improve the survival rate.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Recruiting
- Shanghai General Hospital
-
Contact:
- Xianmin Song, PHD,MD
- Phone Number: 86-18616705298
- Email: Shongxm@sjtu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥18 years old, male or female;
- Patients who received allogeneic peripheral blood hematopoietic stem cell transplantation ;
- Patients must be able to understand and be willing to participate in this study and sign informed consent.-
Exclusion Criteria:
- Non-allogeneic hematopoietic stem cell transplantation patients;
- The expected survival rate is less than 3 months after transplantation;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: allo-PBSCT patients with no NGS text
|
The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NGS results
Time Frame: 3 years
|
positive: VAF>0.2%;
negative: VAF <0.1%
|
3 years
|
MRD by FCM
Time Frame: 3 years
|
posotive:MRD by FCM≥0.01%,
negative:MRD by FCM<0.01%
|
3 years
|
Donor chimerism (DC)
Time Frame: 3 years
|
positive: the chimerism rate increased ((STR < 90%) or FISH > 0.6%);negative:chimerism rate reached(STR > 95% or xy-FISH Donor chromosome > 99.4%)
|
3 years
|
fusion gene or WT1
Time Frame: 3 years
|
positive:WT1/ reference gene, bone marrow >2%;negative:negative fusion gene, WT1/ reference gene <0.6%.
|
3 years
|
relapse
Time Frame: 3 years
|
The number of patients relapse after Allo-PBSCT
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
survival
Time Frame: 3 years
|
overall survival
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHSYXY- NGS-2019003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NGS Monitor MRD
-
Yizhuo ZhangRecruitingPediatric, Solid Tumors, NGSChina
-
Biotronik, Inc.CompletedInsertable Cardiac MonitorUnited States
-
China Medical University, ChinaCompletedSleep | Electroencephalography | Anesthesia MonitorChina
-
Seoul National University HospitalCompleted
-
Center for Epidemiology and Health Research, GermanyAva AGCompleted
-
University of CalgaryCompletedValidation of Respiratory Rate Monitor Versus CapnographyCanada
-
University of California, Los AngelesUniversity of Massachusetts, WorcesterRecruiting
-
Duke UniversityCompletedNo Applicable Condition; Study of Physiologic Monitor Alarms
-
University of California, DavisCompletedAccuracy of Non-invasive Hemoglobin Monitor
-
University of PennsylvaniaTerminatedAdverse Events | SEDLine | Accoustic Respiratory Monitor RAD87 | Advanced Endoscopic ProceduresUnited States
Clinical Trials on NGS patients
-
University of California, San FranciscoNorthern California Institute of Research and Education; Guardant Health, Inc.RecruitingNon-small Cell Lung Cancer | Nodule Solitary PulmonaryUnited States
-
Shanghai Children's HospitalChildren's Hospital affiliated to Chongqing Medical University; Xuzhou maternal...Not yet recruitingPremature Infants | NICU Infants | Conventional NBS-positive Infants
-
Chang Gung Memorial HospitalRecruitingRecurrent Miscarriage | Chromosome Translocation | Genetic Disorders in PregnancyTaiwan
-
Rennes University HospitalCompleted
-
Shanghai Children's HospitalChildren's Hospital of Chongqing Medical University; Northwest Women's and... and other collaboratorsNot yet recruiting
-
Yizhuo ZhangRecruitingPediatric, Solid Tumors, NGSChina
-
Karolinska University HospitalCompletedPancreatic Ductal Adenocarcinoma
-
National Cancer Institute (NCI)RecruitingAcute Lymphoblastic Leukemia | B-AllUnited States
-
The Belgian Society of Medical OncologyRoche Pharma AG; Foundation Medicine; SciensanoRecruiting
-
Chinese Anti-Cancer AssociationUnknown